Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease

BACKGROUND: Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. CASE DIAGNOSIS/TREATMENT: A female infant with massive renal enlargement, respiratory compromise and hyponatraem...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilbert, Rodney D., Evans, Hazel, Olalekan, Kazeem, Nagra, Arvind, Haq, Mushfequr R., Griffiths, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368203/
https://www.ncbi.nlm.nih.gov/pubmed/28194574
http://dx.doi.org/10.1007/s00467-017-3584-9
_version_ 1782517880820072448
author Gilbert, Rodney D.
Evans, Hazel
Olalekan, Kazeem
Nagra, Arvind
Haq, Mushfequr R.
Griffiths, Mark
author_facet Gilbert, Rodney D.
Evans, Hazel
Olalekan, Kazeem
Nagra, Arvind
Haq, Mushfequr R.
Griffiths, Mark
author_sort Gilbert, Rodney D.
collection PubMed
description BACKGROUND: Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. CASE DIAGNOSIS/TREATMENT: A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size. CONCLUSION: Tolvaptan may be a useful treatment for severe neonatal PKD.
format Online
Article
Text
id pubmed-5368203
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-53682032017-04-11 Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease Gilbert, Rodney D. Evans, Hazel Olalekan, Kazeem Nagra, Arvind Haq, Mushfequr R. Griffiths, Mark Pediatr Nephrol Brief Report BACKGROUND: Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. CASE DIAGNOSIS/TREATMENT: A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size. CONCLUSION: Tolvaptan may be a useful treatment for severe neonatal PKD. Springer Berlin Heidelberg 2017-02-13 2017 /pmc/articles/PMC5368203/ /pubmed/28194574 http://dx.doi.org/10.1007/s00467-017-3584-9 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Brief Report
Gilbert, Rodney D.
Evans, Hazel
Olalekan, Kazeem
Nagra, Arvind
Haq, Mushfequr R.
Griffiths, Mark
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
title Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
title_full Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
title_fullStr Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
title_full_unstemmed Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
title_short Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
title_sort tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368203/
https://www.ncbi.nlm.nih.gov/pubmed/28194574
http://dx.doi.org/10.1007/s00467-017-3584-9
work_keys_str_mv AT gilbertrodneyd tolvaptantreatmentforsevereneonatalautosomaldominantpolycystickidneydisease
AT evanshazel tolvaptantreatmentforsevereneonatalautosomaldominantpolycystickidneydisease
AT olalekankazeem tolvaptantreatmentforsevereneonatalautosomaldominantpolycystickidneydisease
AT nagraarvind tolvaptantreatmentforsevereneonatalautosomaldominantpolycystickidneydisease
AT haqmushfequrr tolvaptantreatmentforsevereneonatalautosomaldominantpolycystickidneydisease
AT griffithsmark tolvaptantreatmentforsevereneonatalautosomaldominantpolycystickidneydisease

Ejemplares similares